Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;20(3):171-6.
doi: 10.3109/1354750X.2015.1046932. Epub 2015 Jul 8.

Chromogranin A levels and mortality in patients with severe sepsis

Chih-Hsin Hsu  1 , Luis F Reyes, Carlos J Orihuela, Ricardo Buitrago, Antonio Anzueto, Nilam J Soni, Stephanie Levine, Jay Peters, Cecilia A Hinojosa, Stefano Aliberti, Oriol Sibila, Alejandro Rodriguez, James D Chalmers, Ignacio Martin-Loeches, Jose Bordon, Jose Blanquer, Francisco Sanz, Pedro J Marcos, Jordi Rello, Jordi Solé-Violán, Marcos I Restrepo
Affiliations

Chromogranin A levels and mortality in patients with severe sepsis

Chih-Hsin Hsu et al. Biomarkers. 2015.

Abstract

Context: Chromogranin A (CgA) is a novel biomarker with potential to assess mortality risk of patients with severe sepsis.

Objective: Assess association of CgA levels and mortality risk of severely septic patients.

Methods: Serum CgA levels were measured in 50 hospitalized, severely septic patients with organ failure <48 h.

Results: Higher CgA levels trended toward higher ICU and hospital mortality. Patients without cardiovascular disease who died in the ICU had higher median (IQR) CgA levels 602.3 (343.3, 1134.3) ng/ml versus 205.5 (130.7, 325.9) ng/ml, p = 0.01.

Conclusions: High CgA levels predict ICU mortality in severely septic patients without prior cardiovascular disease.

Keywords: Biological marker; Chromogranin A; cardiovascular diseases; mortality; sepsis.

PubMed Disclaimer

Conflict of interest statement

All authors have no conflict of interest

Figures

Figure 1
Figure 1
Serum CgA levels comparing ICU and hospital survivors vs. non-survivors, and the need for vasopressors/inotropes vs. no need for vasopressors/inotropes. All patients with severe sepsis are shown in Panel A and patients without prior cardiovascular disease are shown in Panel B.
Figure 2
Figure 2
Proportion of patients with severe sepsis (Panel A) and those without prior cardiovascular disease (Panel B) who died during the ICU and hospital stratified by serum CgA levels.
See this image and copyright information in PMC

References

    1. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet. 2010;376:1339–46. - PMC - PubMed
    1. Angelone T, Mazza R, Cerra MC. Chromogranin-A: a multifaceted cardiovascular role in health and disease. Curr Med Chem. 2012;19:4042–50. - PubMed
    1. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med. 2001;29:S109–16. - PubMed
    1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B Network CU-R. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med. 2003;168:165–72. - PubMed
    1. Arora S, Singh P, Singh PM, Trikha A. Procalcitonin levels in survivors and non survivors of Sepsis: Systematic review and Meta-analysis. Shock 2014 - PubMed

Publication types